Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Buy
56
BCPC Quote, Financials, Valuation and Earnings
Last price:
$155.93
Seasonality move
:
7.89%
Day range:
$154.15 - $157.75
52-week range:
$137.69 - $186.03
Dividend yield:
0.56%
P/E ratio:
37.41x
P/S ratio:
5.30x
P/B ratio:
4.21x
Volume:
297K
Avg. volume:
223.5K
1-year change:
12.05%
Market cap:
$5.1B
Revenue:
$953.7M
EPS (TTM):
$4.17
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Balchem has 25.63% upside to fair value with a price target of $196.00 per share.
BCPC vs. S&P 500
-
Over the past 5 trading days, Balchem has underperformed the S&P 500 by -2.3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Balchem does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Balchem has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Balchem reported revenues of $250.5M.
Earnings Growth
-
Balchem has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Balchem reported earnings per share of $1.13.
Enterprise value:
5.2B
EV / Invested capital:
3.74x
Price / LTM sales:
5.30x
EV / EBIT:
27.29x
EV / Revenue:
5.42x
PEG ratio (5yr expected):
2.10x
EV / Free cash flow:
34.68x
Price / Operating cash flow:
33.90x
Enterprise value / EBITDA:
22.07x
Gross Profit (TTM):
$342.9M
Return On Assets:
8.58%
Net Income Margin (TTM):
14.16%
Return On Equity:
11.92%
Return On Invested Capital:
9.89%
Operating Margin:
20.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $946M | $929.6M | $964.5M | $239.7M | $250.5M | |
| Gross Profit | $282.1M | $310.4M | $342.9M | $81.5M | $88.2M | |
| Operating Income | $141.3M | $166.5M | $192.2M | $41.7M | $51M | |
| EBITDA | $194.1M | $222.4M | $236.9M | $55.9M | $61.9M | |
| Diluted EPS | $3.06 | $3.54 | $4.17 | $0.89 | $1.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $281.2M | $319.8M | $335.6M | $324.9M | $340.2M | |
| Total Assets | $1.2B | $1.2B | $1.6B | $1.6B | $1.6B | |
| Current Liabilities | $88.8M | $123.5M | $116.5M | $124.4M | $139.6M | |
| Total Liabilities | $319.7M | $321.2M | $655.3M | $509.9M | $408.9M | |
| Total Equity | $849.5M | $873.7M | $973.4M | $1.1B | $1.2B | |
| Total Debt | $153.6M | $128.6M | $431.6M | $301.6M | $190M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $166.4M | $182.3M | $185.1M | $33.4M | $36.5M | |
| Cash From Investing | -$416M | -$31.5M | -$58.9M | -$6.7M | -$5.9M | |
| Cash From Financing | $248.2M | -$150M | -$135.8M | -$30M | -$32M | |
| Free Cash Flow | $117M | $147.2M | $150.8M | $26.5M | $30.9M | |
BCPC
Sector
Market Cap
$5.1B
$18M
Price % of 52-Week High
83.86%
62.5%
Dividend Yield
0.56%
0%
Shareholder Yield
1.07%
1.27%
1-Year Price Total Return
12.05%
-15.52%
Beta (5-Year)
0.752
0.917
Dividend yield:
0.56%
Annualized payout:
$0.87
Payout ratio:
20.72%
Growth streak:
15 years
Technicals
8-day SMA
Sell
Level
$156.77
200-day SMA
Sell
Level
$168.58
Bollinger Bands (100)
Sell
Level
157.75 - 171.71
Chaikin Money Flow
Buy
Level
30.1M
20-day SMA
Sell
Level
$158.72
Relative Strength Index (RSI14)
Sell
Level
43.49
ADX Line
Sell
Level
28.56
Williams %R
Neutral
Level
-46.1759
50-day SMA
Sell
Level
$164.05
MACD (12, 26)
Sell
Level
-2.23
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
26.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.4708)
Buy
CA Score
(Annual)
Level (1.1845)
Buy
Beneish M-Score
(Annual)
Level (-2.636)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.2069)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Stock Forecast FAQ
In the current month, BCPC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCPC average analyst price target in the past 3 months is $196.00.
-
Where Will Balchem Stock Be In 1 Year?
According to analysts, the consensus estimate is that Balchem share price will rise to $196.00 per share over the next 12 months.
-
What Do Analysts Say About Balchem?
Analysts are divided on their view about Balchem share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Balchem is a Sell and believe this share price will drop from its current level to $180.00.
-
What Is Balchem's Price Target?
The price target for Balchem over the next 1-year time period is forecast to be $196.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCPC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Balchem is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BCPC?
You can purchase shares of Balchem via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Balchem shares.
-
What Is The Balchem Share Price Today?
Balchem was last trading at $155.93 per share. This represents the most recent stock quote for Balchem. Yesterday, Balchem closed at $156.01 per share.
-
How To Buy Balchem Stock Online?
In order to purchase Balchem stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is up 23.1% over the past day.
Sell
35
RGC alert for Apr 30
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 14.88% over the past day.
